Allist

Shanghai Allist Pharmaceuticals Co., Ltd., established in 2004, is a high-tech enterprise integrating new drug R&D, production, and sales. With the mission of "Technology Cares for Life," Allist regards the development of innovative drugs and the creation of personalized treatment systems as its core competitiveness. Headquartered in Shanghai Zhoupu Medical Park, the group has R&D centers, marketing centers, and a Jiangsu production base. Allist is committed to innovative research in areas such as anti-tumor, cardiovascular, and diabetes treatments, having obtained over 50 domestic and international patent authorizations and multiple new drug filings. Examples include Allisartan Isoproxil, a 1.1-class new chemical drug for hypertension; Alflutinib, a molecularly targeted anti-tumor 1.1-class new drug; and a blockbuster product, Alflutinib Mesylate, a third-generation EGFR inhibitor, all of which possess fully independent intellectual property rights and undertake major national new drug creation projects. The clinical research of Allisartan Isoproxil was listed as a key project under the "863" Modern Medicine Major Disease Program of the Ministry of Science and Technology, and it received its new drug certificate and successfully launched on the market in 2012. After 18 years of accumulation in innovative talent, platforms, and culture, Allist is now in a stage of rapid development following years of groundwork. In 2019, it completed a total financing of RMB 1.38 billion, and in December 2020, it was officially listed on the Science and Technology Innovation Board. Allist's fully self-developed blockbuster product, Aiverza, a targeted tumor therapy for non-small cell lung cancer, was marketed in March 2020. All these favorable factors have laid a solid foundation for the company's accelerated growth and provided a broad development platform for talented individuals committed to human health. We look forward to your joining us to share the fruits of development!